{'fraction_non_alphanumeric': 0.02359882005899705, 'fraction_numerical': 0.0019665683382497543, 'mean_word_length': 5.786666666666667, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
The effects of beta-adrenoceptor blocking drugs on non-esterified fatty acid release from adipocytes.

A review is presented of the effects of beta-adrenoceptor blocking agents on lipolysis in adipose tissue. Considerable species differences appear to exist between the pharmacological characteristics of beta-adrenoceptors in adipocytes of rat, guinea pig, dog, cat, swine and man. Human adipocyte beta-adrenoceptors probably consist of two subtypes; insufficient data are available to ascertain whether they represent "classical" beta 1- and beta 2-adrenoceptors or atypical receptors similar but not identical to those in the rat. In vivo studies in man suggest that non-cardioselective beta-adrenoceptor blocking agents are more effective antilipolytic agents than cardioselective beta-adrenoceptor antagonists. No clinical evidence could be found to suggest that the quantitative differences in antilipolytic potency between cardioselective and non-cardioselective agents have more than speculative significance.